Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.49 - $10.8 $425,095 - $707,400
65,500 Added 102.5%
129,400 $1.08 Million
Q2 2024

Aug 14, 2024

BUY
$4.54 - $8.2 $256,510 - $463,299
56,500 Added 763.51%
63,900 $435,000
Q1 2024

May 15, 2024

SELL
$4.86 - $8.19 $40,338 - $67,977
-8,300 Reduced 52.87%
7,400 $48,000
Q4 2023

Feb 14, 2024

SELL
$3.37 - $6.86 $12,469 - $25,382
-3,700 Reduced 19.07%
15,700 $101,000
Q3 2023

Nov 14, 2023

BUY
$4.7 - $8.55 $940 - $1,710
200 Added 1.04%
19,400 $97,000
Q2 2023

Aug 14, 2023

BUY
$7.35 - $13.29 $141,120 - $255,167
19,200 New
19,200 $168,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $220M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.